Elicio Therapeutics, Inc.
ELTX
$4.80
$0.040.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.77M | 3.14M | 2.74M | 2.68M | 3.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.48M | 10.34M | 10.92M | 10.24M | 9.39M |
| Operating Income | -13.48M | -10.34M | -10.92M | -10.24M | -9.39M |
| Income Before Tax | -14.00M | -18.84M | -7.23M | -11.83M | -8.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.00M | -18.84M | -7.23M | -11.83M | -8.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.00M | -18.84M | -7.23M | -11.83M | -8.95M |
| EBIT | -13.48M | -10.34M | -10.92M | -10.24M | -9.39M |
| EBITDA | -13.39M | -10.27M | -10.84M | -10.16M | -9.31M |
| EPS Basic | -1.03 | -1.39 | -0.64 | -1.15 | -1.05 |
| Normalized Basic EPS | -0.64 | -0.87 | -0.40 | -0.72 | -0.66 |
| EPS Diluted | -1.03 | -1.39 | -0.64 | -1.15 | -1.05 |
| Normalized Diluted EPS | -0.64 | -0.87 | -0.40 | -0.72 | -0.66 |
| Average Basic Shares Outstanding | 13.65M | 13.58M | 11.28M | 10.27M | 8.54M |
| Average Diluted Shares Outstanding | 13.65M | 13.58M | 11.28M | 10.27M | 8.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |